Why is this ASX All Ords biotech share crashing 12% today?

This biotech is having a day to forget on Tuesday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day.

In afternoon trade, the biotechnology company's shares are down 12% to $1.48.

This makes the Paradigm share price one of the worst performers on the All Ordinaries index today.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

Why is the Paradigm share price sinking?

Investors have been hitting the sell button on Tuesday after Paradigm announced the surprise exit of its CEO and managing director, Marco Polizzi.

According to the release, Mr Polizzi has stepped down from his role immediately and will cease employment with the company on 20 February.

Paradigm only announced the appointment of Polizzi at the end of May, with the experienced pharmaceutical industry executive commencing in the role on 1 July. At the time, the company hyped up his appointment, describing him as "a CEO with the skills to fully unlock the commercial value of the company."

No reason was given for the CEO's exit after just a few months with the company. Nor did Polizzi leave a parting comment, which is never a good look and could potentially be an indication of boardroom tensions.

What now?

The Paradigm board has acted quickly and appointed the company's founder and non-executive chairman Paul Rennie as its new leader. He said:

I am pleased to advise that the personal circumstances that originally required my stepping down from the Managing Director role in 2021, have now been successfully resolved. I look forward to working closely again with the Paradigm executive team and the Board in continuing our journey together.

Following today's decline, the Paradigm share price has now lost almost a third of its value over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »